Journal of Jianghan University (Natural Science Edition) ›› 2020, Vol. 48 ›› Issue (6): 23-32.doi: 10.16389/j.cnki.cn42-1737/n.2020.06.003

Previous Articles     Next Articles

Mechanism Exploration of Jinyebaidu Particles Against COVID- 19 Based on Network Pharmacology

YUAN Fahu,LIU Li,BA Ruiqi,CHEN Jiangyuan,HUANG Lixia,ZHU Shuxiu*   

  1. School of Medicine,Jianghan University,Wuhan 430056,Hubei,China
  • Online:2020-12-28 Published:2020-12-18
  • Contact: 朱书秀
  • Supported by:
    国家自然科学基金资助项目(81674060)

Abstract: Objective To explore the pharmacological mechanism of Jinyebaidu Particles in the treatment of coronavirus disease 2019 (COVID-19). Methods Through searching Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP)and Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM) to select the chemical constituents and action targets of Lonicerae Japonicae Flos,Houttuyniae Herba,Isatidis Folium,Taraxacum mongolicum Hand.-Mazz in Jinyebaidu Particles. The disease-related target genes were obtained by consulting Online Mendelian Inheritance in Man (OMIM) and GeneCards database,and then the drug-active molecules-target gene action network was constructed using Cytoscape software. Gene ontology (GO) functional annotation and enrichment analysis based on Kyoto Encyclopedia of Genes and Genomes(KEGG) pathways were conducted by the R package cluster Profiler to predict the mechanism of action of Jinyebaidu Particles on COVID-19. Results A total of 31 active molecules and 110 target genes were screened,mainly including PTGS2,AR,ESR1,PPARG,PRSS1,NOS2,NR3C2 and other core targets. Enrichment analysis revealed 2 138 GO items(P < 0. 05)and 134 KEGG signaling pathways (P < 0. 05). The main enrichment pathways included AGE-RAGE signaling pathway,atherosclerosis,TNF-α signaling pathway,Influenza A pathway. Conclusion The active compounds of Jinyebaidu Particles can act on core inflammatory pathways such as TNF signaling,thus exerting antioxidant damage and anti-inflammatory effects on COVID-19.

Key words: Jinyebaidu, particles, coronavirus disease 2019 (COVID-19), pneumonia, network pharmacology

CLC Number: